Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies

References

• Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(2):ii14–7.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970.
   PubMed Web of Science ®Google Scholar
• Stolwijk C, van Onna M, Boonen A, et al. Global prevalence of spondyloarthritis: a systematic review and Meta-regression analysis. Arthritis Care Res (Hoboken). 2016;68(9):1320–1331.
   PubMed Web of Science ®Google Scholar
• Merola JF, Shrom D, Eaton J, et al. Patient perspective on the burden of skin and joint symptoms of psoriatic arthritis: results of a multi-national patient survey. Rheumatol Ther. 2019;6(1):33–45.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–881.e30.
   PubMed Web of Science ®Google Scholar
• de Vlam K, Merola JF, Birt JA, et al. Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational, cross-sectional study. Rheumatol Ther. 2018;5(2):423–436.
   PubMed Web of Science ®Google Scholar
• Merola JF, Dennis N, Chakravarty SD, et al. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020. Clin Rheumatol. 2021;40(10):4061–4070.
   PubMed Web of Science ®Google Scholar
• Merola JF, Herrera V, Palmer JB. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. Clin Rheumatol. 2018;37(10):2751–2761.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency: Science, Medicines, Health [Internet]. Assessment report: Xeljanz, International non-proprietary name: tofacitinib. Amsterdam, The Netherlands: European Medicines Agency; c1995–2022; 2017. Available from: https://www.ema.europa.eu/en/documents/assessment-report/xeljanz-epar-public-assessment-report_en.pdf
   Google Scholar
• European Medicines Agency: Science, Medicines, Health [Internet]. Xeljanz (tofacitinib citrate): summary of product characteristics. Amsterdam, The Netherlands: European Medicines Agency; c1995–2022; 2022. Available from: https://www.medicines.org.uk/emc/medicine/33167
   Google Scholar
• US Food and Drug Administration [Internet]. Xeljanz® (tofacitinib): highlights of prescribing information. Silver Spring (MD): US Food and Drug Administration; c2022; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203214s028,208246s013,213082s003lbl.pdf
   Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–1536.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–1550.
   PubMed Web of Science ®Google Scholar
• Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL balance long-term extension study. Lancet Rheumatol. 2021;3(4):E270–83.
   Google Scholar
• Merola JF, Papp KA, Nash P, et al. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. J Eur Acad Dermatol Venereol. 2020;34(12):2809–2820.
   PubMed Web of Science ®Google Scholar
• Ständer S, Luger T, Cappelleri JC, et al. Validation of the Itch Severity Item as a measurement tool for pruritus in patients with psoriasis: results from a phase 3 tofacitinib program. Acta Derm Venereol. 2018;98(3):340–345.
   PubMed Web of Science ®Google Scholar
• Langley RGB, Feldman SR, Nyirady J, et al. The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23–31.
   PubMed Web of Science ®Google Scholar
• Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38(5):898–903.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use . Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125(4):659–664.
   PubMed Web of Science ®Google Scholar
• Basra MKA, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27–33.
   PubMed Web of Science ®Google Scholar
• Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores [abstract]. Br J Dermatol. 2002;147(62):50.
   Google Scholar
• Ware JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36v2 Health Survey. 2nd ed. Lincoln (RI): Quality Metric Incorporated; 2007.
   Google Scholar
• Cappelleri JC, Zou KH, Bushmakin AG, et al. Patient-reported outcomes: measurement, implementation and interpretation. Boca Raton (FL): Chapman & Hall/CRC Press; 2013.
   Google Scholar
• Coates LC, Bushmakin AG, FitzGerald O, et al. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. Arthritis Res Ther. 2021;23(1):94.
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019;5(1):e000806.
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019;5(1):e000808.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019;78(9):1215–1219.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Thyssen JP, Simpson EL, et al. Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes. Am J Clin Dermatol. 2021;22(4):541–554.
   PubMed Web of Science ®Google Scholar
• Dures E, Shepperd S, Mukherjee S, et al. Treat-to-target in PsA: methods and necessity. RMD Open. 2020;6(1):e001083.
   PubMed Web of Science ®Google Scholar